Methdilazine
An antihistamine used to relieve itching caused by allergic skin conditions such as hives and eczema, this medication also has mild sedative properties. It works by blocking histamine, a substance in the body that causes allergic symptoms.
Masse moléculaire
296,4000 g/mol
LogP
5,20
TPSA
31,80 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Structure 2D
Cite this structure
Embed this structure
SMILES
CN1CCC(CN2c3ccccc3Sc3ccccc32)C1
InChI
InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
Molecular Formula
C18H20N2S
HBD / HBA
- / 3
Liaisons Rotatives
2
Atomes Lourds
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
An antihistamine used to relieve itching caused by allergic skin conditions such as hives and eczema, this medication also has mild sedative properties. It works by blocking histamine, a substance in the body that causes allergic symptoms.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Methdilazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200959. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 14677. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="methdilazine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/methdilazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/methdilazine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/methdilazine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="methdilazine"></drugfyi-drug>